Also, Catalent has recently acquired an exclusive license to market Redwood Bioscience’s SMARTag precision protein-chemical engineering technology for the development of advanced antibody drug conjugates (ADCs). Redwood’s site-specific protein modification and linker technologies enable the generation of homogenous bioconjugates engineered to enhance potency, safety and stability. Catalent will combine its GPEx cell line expression system with SMARTag for the rapid development of stable, high yi...